Login / Signup

Novel µ opioid antagonists derived from the µ opioid agonists endomorphin and [Dmt1 ]DALDA (H-Dmt-D-Arg-Phe-Lys-NH2 ).

Saijian ShiJian XuLingLing FengXin FanZhen ChenYajuan QinNga N ChungTingyou LiPeter W Schiller
Published in: Chemical biology & drug design (2020)
Hybrid analogues of the µ opioid agonists endomorphin and [Dmt1 ]DALDA (H-Dmt-D-Arg-Phe-Lys-NH2 , Dmt = 2',6'-dimethyltyrosine) containing cis-4-amino-Pro, trans-4-amino-Pro, cis-4-aminoethyl-Pro or cis-4-guanidinylethyl-Pro in the 2 position of the peptide sequence were synthesized. None of the compounds retained high µ opioid agonist activity and, unexpectedly, substitution of cis-4-amino-Pro resulted in a novel class of potent µ opioid antagonists. In particular, the compound H-Dmt-cis-4-amino-Pro-Trp-Lys-NH2 (CZ-1) turned out to be a highly selective µ opioid antagonist with ~1 nM µ receptor binding affinity.
Keyphrases
  • chronic pain
  • pain management
  • anti inflammatory
  • room temperature
  • photodynamic therapy
  • molecular docking